Option Care Health (OPCH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Nov, 2026Executive summary
Merger agreement signed October 5, 2026; each eligible share converts to $32.05 cash, a ~42% premium to the October 2, 2026 closing price of $22.64.
CD&R-managed funds and McKesson are financing the ~$5.8 billion transaction; closing is expected in H1 2027, subject to stockholder and regulatory approvals.
If completed, the surviving corporation becomes a wholly owned subsidiary of Onyx Bidco; shares will be delisted from Nasdaq and deregistered under the Exchange Act.
Voting matters and shareholder proposals
December 15, 2026 virtual special meeting: vote on merger adoption, advisory merger-related executive compensation, and adjournment if needed for votes, quorum, or supplemental disclosures.
Board unanimously recommends FOR all three proposals; merger adoption requires affirmative votes from holders of a majority of outstanding shares entitled to vote.
Advisory compensation approval is non-binding and not a closing condition; contractual merger-related compensation remains payable if the deal closes, subject to applicable conditions.
As of the November 3, 2026 record date, 149,799,704 shares were entitled to vote; abstentions and non-votes have the same effect as AGAINST on merger adoption.
Board of directors and corporate governance
The board unanimously found the transaction fair, advisable, and in stockholders’ best interests after reviewing alternatives and negotiating terms; it directed submission of the merger agreement for a vote.
Sale process included outreach to 17 third parties and three non-binding bids; the board selected the $32.05 Investor Group offer, citing completed diligence, price, timing, and execution certainty.
Centerview’s October 5, 2026 opinion found the $32.05 consideration fair from a financial point of view; its DCF per-share range was $25.65–$34.05.
At closing, Merger Sub’s directors become directors of the surviving corporation; existing officers continue, subject to successors or earlier removal, resignation, or death.
Latest events from Option Care Health
- Q3 growth persisted amid CID pressure as a $32.05/share acquisition awaited approval.OPCH
Q3 2026 - $32.05-per-share cash merger wins unanimous board backing, pending shareholder and regulatory approval.OPCH
Proxy filing - Unanimously approved $5.8 billion cash acquisition expected to close in H1 2027.OPCH
Proxy filing - CD&R and McKesson propose a $32.05/share cash acquisition, pending stockholder and regulatory approvals.OPCH
Proxy filing - Growth in acute and specialty therapies, portfolio diversification, and new rare drugs drive momentum.OPCH
Morgan Stanley 24th Annual Global Healthcare Conference - Delivered strong 2026 growth with $1.44B Q2 revenue and national home infusion leadership.OPCH
Investor presentation - Q2 2026 delivered higher revenue, earnings, and cash flow, with strong acute therapy growth.OPCH
Q2 2026 - Balanced growth, payer partnerships, and strong cash flow drive expansion and resilience.OPCH
Bank of America 2025 Healthcare Conference - Q3 revenue up 17% but net income down 4.3% as supply chain and pricing issues weigh on results.OPCH
Q3 2024